JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1992; 19:894-898
© 1992 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greene, H.
Right arrow Articles by Henthorn, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greene, H.
Right arrow Articles by Henthorn, R.

The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II

HL Greene, DM Roden, RJ Katz, RL Woosley, DM Salerno, and RW Henthorn

Department of Medicine, University of Washington, Seattle.

The Cardiac Arrhythmia Suppression Trial (CAST) was a study designed to test the hypothesis that suppression of ventricular premature complexes after a myocardial infarction would improve survival. Preliminary results showed that suppression of ventricular premature complexes with encainide and flecainide worsened survival, and the CAST continued as the CAST-II with moricizine compared with its placebo. The protocol for the CAST-II was changed to attempt to enroll patients more likely to experience serious arrhythmias. The enrollment time was narrowed to 4 to 90 days after myocardial infarction; the qualifying ejection fraction was lowered to less than or equal to 0.40; a higher dose of moricizine could be used; early titration itself was double-blind with a placebo, and the definition of disqualifying ventricular tachycardia was changed to allow patients with more serious arrhythmias to be entered into the trial. The Cardiac Arrhythmia Suppression Trial-II was subsequently terminated prematurely because 1) patients treated with moricizine had an excessive cardiac mortality rate during the 1st 2 weeks of exposure to the drug, and 2) there appeared to be little chance of showing a long-term survival benefit from treatment with moricizine. This report outlines the rationale behind the Cardiac Arrhythmia Suppression Trial and the reasons for selection of the drugs used in the CAST and CAST-II.


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
S. P. Glasser and G. Howard
Clinical trial design issues: at least 10 things you should look for in clinical trials.
J. Clin. Pharmacol., October 1, 2006; 46(10): 1106 - 1115.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
J. S. March, S. G. Silva, S. Compton, M. Shapiro, R. Califf, and R. Krishnan
The Case for Practical Clinical Trials in Psychiatry
Am J Psychiatry, May 1, 2005; 162(5): 836 - 846.
[Abstract] [Full Text] [PDF]


Home page
Qual Saf Health CareHome page
A H Morris
Decision support and safety of clinical environments
Qual. Saf. Health Care, March 1, 2002; 11(1): 69 - 75.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
F. Di Maio, V. Rizzo, S. V. Campbell, F. Petretto, A. Corbellini, A. Bianchi, G. Bianco, F. Meloni, V. Bernardo, and D. Tallarico
Effects of Cardiac Rehabilitation on Atrial Wave in Patients After Myocardial Infarction
Angiology, December 1, 2001; 52(12): 827 - 833.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
B. Darpo
Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K70 - K80.
[Abstract] [PDF]


Home page
CirculationHome page
S. Ranger and S. Nattel
Determinants and Mechanisms of Flecainide-Induced Promotion of Ventricular Tachycardia in Anesthetized Dogs
Circulation, September 1, 1995; 92(5): 1300 - 1311.
[Abstract] [Full Text]


Home page
CirculationHome page
S. Goldstein, M. M. Brooks, R. Ledingham, H. L. Kennedy, A. E. Epstein, Y. Pawitan, and J. T. Bigger
Association Between Ease of Suppression of Ventricular Arrhythmia and Survival
Circulation, January 1, 1995; 91(1): 79 - 83.
[Abstract] [Full Text]


Home page
NEJMHome page
D. M. Roden
Risks and Benefits of Antiarrhythmic Therapy
N. Engl. J. Med., September 22, 1994; 331(12): 785 - 791.
[Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1992 by the American College of Cardiology Foundation.